Polycarbophil

Identification

Name
Polycarbophil
Accession Number
DB09311
Description

Polycarbophil calcium is a synthetic polymer manufactured from the cross-linking of polyacrylic acid with divinyl glycol and a calcium counter-ion. Polycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.

Type
Small Molecule
Groups
Experimental
Synonyms
  • Policarbofila
  • Polycarbofil
  • Polycarbophile
  • Polycarbophilum
External IDs
  • WL 140
  • WL-140

Pharmacology

Indication

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Mechanism of action

It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.

Absorption

Calcium polycarbophil is not absorbed from the intestine.

Volume of distribution

Calcium polycarbophil is not absorbed from the intestine.

Protein binding

Calcium polycarbophil is not absorbed from the intestine.

Metabolism

Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.

Route of elimination

Excreted in feces.

Half-life

Calcium polycarbophil is not absorbed from the intestine.

Clearance

Calcium polycarbophil is not absorbed from the intestine.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Polycarbophil.
AclidiniumThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Polycarbophil is combined with Alloin.
AmantadineThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Polycarbophil.
AmiodaroneThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amiodarone.
AmitriptylineThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amitriptyline.
AmlodipineThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amlodipine.
AmobarbitalThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Amobarbital.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
International/Other Brands
Fibercon / Mitrolan

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
W25LM17A4W
CAS number
9003-97-8

References

General References
  1. Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [PubMed:6765389]
  2. Monograph [Link]
  3. webmd [Link]
KEGG Drug
D03306
PubChem Substance
347910435
Wikipedia
Polycarbophil_calcium
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingSupportive CareLong-Term Survivors / Malignant Neoplasm of Female Breast / Postmenopausal Syndrome / Vulvovaginal Atrophy1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on November 16, 2015 14:57 / Updated on December 02, 2020 00:54

Drug dev 2